Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Co. Ltd.

www.daiichisankyo.com

Latest From Daiichi Sankyo Co. Ltd.

First Filing, In Japan, For Daiichi’s Lead ADC As Others Progress

In a further positive step for its oncology ambitions, Japanese company files first submission for promising lead antibody-drug conjugate, partnered globally with AstraZeneca, while other pipeline ADCs mark development progress.

Cancer Clinical Trials

ENTRUST Bolsters Edoxaban As VKA Alternative In AF Patients

Daiichi drug shows non-inferiority to standard antithrombotic regimen in atrial fibrillation patients, adding to evidence supporting Factor Xa inhibitor's use.

Clinical Trials Comparative Effectiveness

Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen

The latest drug development news and highlights from our US FDA Performance Tracker.
Approvals Drug Review

AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon

AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.

Drug Review Launches
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register